Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 4/20 | 1.00 |
| ▸ | PRKCG known ✓ | P05129 | 5/20 | 0.98 |
| ▸ | PRKCZ known ✓ | Q05513 | 5/20 | 0.98 |
| ▸ | PRKCD known ✓ | Q05655 | 5/20 | 0.98 |
| ▸ | PRKD3 known ✓ | O94806 | 4/20 | 0.98 |
| ▸ | PRKCB known ✓ | P05771 | 4/20 | 0.98 |
| ▸ | PRKCA known ✓ | P17252 | 4/20 | 0.98 |
| ▸ | PRKCH known ✓ | P24723 | 4/20 | 0.98 |
| ▸ | PRKCI known ✓ | P41743 | 4/20 | 0.98 |
| ▸ | PRKCE known ✓ | Q02156 | 4/20 | 0.98 |
| ▸ | PRKCQ known ✓ | Q04759 | 4/20 | 0.98 |
| ▸ | PRKD1 known ✓ | Q15139 | 4/20 | 0.98 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.98 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.98 |
| ▸ | FLT3 known ✓ | P36888 | 9/20 | 0.76 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.57 |
| ▸ | PRKACA | P17612 | 6/20 | 1.00 |
| ▸ | PRKACG | P22612 | 4/20 | 1.00 |
| ▸ | PRKACB | P22694 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL905696 | 1.00 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Hydrochloric Acid SCHEMBL29664044 | 1.00 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Hydrochloric Acid SCHEMBL29967768 | 1.00 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Hydrochloric Acid SCHEMBL1048972 | 1.00 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| SCHEMBL29967929 | 0.99 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| SCHEMBL123495 | 0.99 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| SCHEMBL123496 | 0.99 | PRKACA (1.00) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Bromide SCHEMBL3347119 | 0.98 | PRKACA (0.98) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Bromide SCHEMBL3347113 | 0.98 | PRKACA (0.98) | PRKACAROCK2PRKACGPRKACBMAPK1 | |
| Hydrochloric Acid SCHEMBL9482815 | 0.90 | PRKACA (0.82) | PRKACAROCK2PRKACGPRKACBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | claimed |
| US-9006394-B2 | Peptide-presenting surfaces for long-term culture of pluripotent cells | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-04-14 | — | — | US | claimed |
| US-20140287505-A1 | PEPTIDE-PRESENTING SURFACES FOR LONG-TERM CULTURE OF PLURIPOTENT CELLS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2014-09-25 | — | — | US | claimed |
| US-8648170-B2 | Peptide-presenting surfaces for long-term culture of pluripotent cells | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-02-11 | — | — | US | claimed |
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | disclosed |
| CN-117999073-A | Use of nadolol to treat chronic obstructive pulmonary disease by blocking the inhibitor protein-2 pathway | 慢性呼吸道治疗有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | disclosed |
| US-20230383247-A1 | Methods and Culture Substrates for Controlled Induction of Biomimetic Neural Tissues Comprising Singular Rosette Structures | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2023-11-30 | — | — | US | disclosed |
| WO-2023215423-A2 | METHODS OF GENERATING THREE-DIMENSIONAL RETINAL ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023196974-A1 | GENERATING ALLOGENIC ENDOTHELIAL CELL-SEEDED VASCULAR GRAFTS AND METHODS OF USE THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-10-12 | — | — | WO | disclosed |
| US-11767508-B2 | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116519644-A | Method for analyzing protein kinase activity by AuNPs coupling single-molecule fluorescence imaging | 南开大学 | 2023-08-01 | — | — | CN | disclosed |
| US-20080171385-A1 | CULTURE OF STEM CELLS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2008-07-17 | — | — | US | disclosed |
| US-20070041992-A1 | Compositions and methods for inactivating or suppressing inflammatory cells | NEW YORK UNIVERSITY | 2007-02-22 | — | — | US | disclosed |
| US-20030225527-A1 | Crystals and structures of MST3 | SGX PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003083060-A2 | CRYSTALS AND STRUCTURES OF MST3 | STRUCTURAL GENOMIX, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| EP-1022029-A1 | NOOTROPIC AGENT | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5245034-A | Compound having vessel smooth muscle relaxation activity | Hidaka, Kiroyoshi (JP) | 1993-09-14 | — | — | US | disclosed |
| US-5216150-A | Muscle relaxant; enzyme inhibitor and platelet aggutination inhibitor | Hidaka, Hiroyoshi (JP) | 1993-06-01 | — | — | US | disclosed |
| US-5081246-A | Isoquinolino sulfonamino derivatives | Hidaka, Hiroyoshi (JP) | 1992-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | ROCK2 315/4885PRKCG 586/4885PRKCZ 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.